FDA MAP
  • Home
  • Training
    • WORKSHOPS
    • WEBINARS
    • CUSTOM TRAINING
  • SERVICES
    • REGULATORY SERVICES
    • FDA AUDITING
    • QUALITY ASSURANCE
    • CLINICAL TRIAL SERVICES
  • News Releases
  • About Us
FDAMap News 2017
Newsletter - December 21, 2017 (Least Burdensome Approach: FDA Says Do Less to Succeed More)

​Newsletter - December 14, 2017 (FDA’s Relaxed Software Regulations Opens Doors to The Digital Doctor | FDA Measures for Early Feasibility Studies for Devices Bears Fruit)

​Newsletter - December 7, 2017 (FDA Takes Unconventionally Hands-On Role to Approve New Technology | Regenerative Medicine and FDA: Echo Chamber or Calm before the Storm?)

​Newsletter - November 30, 2017 (No, FDA Did Not Change Stem Cell Regulations As Advertised | Widely Available Supplements Contain Unapproved Drugs

​Newsletter - November 16, 2017 (Can False General Health Genetic Tests Hurt the Consumer | Real World Testing Data and FDA Acceptance of Real World Evidence)


​Newsletter - November 9, 2017 (FDA Exempts Most DTC Genetics Tests From 510k | Menu Labeling Simplified by FDA  )

Newsletter - November 2, 2017 (Physician’s Perspective on Simplifying Clinical Trials | FDA Follows Through on its Promise to Recognize European GMP Audits)

Newsletter - October 26, 2017 (Compounding Pharmacy Openly Flouts FDA Regulations | FDA’s Tacit Encouragement of Interchangeability of Biosimilars)

Newsletter - October 19, 2017 (FDA’s Audit Manual Updated: Surprisingly No Surprising Changes | Orphan Drug is Generally Not the First Step to Non-Orphan Approval)

Newsletter - October 12, 2017 (FDA’s “Love”-Less Warning Letter to a Boston Bakery: Food GMP Overkill | CTTI Suggests Ways to Reduce “One And Done” Clinical Investigators)

Newsletter - October 5, 2017 (California Does What FDA Can’t: Require Unapproved Stem Cell Clinics to Inform Patients | FDA Relaxes eCTD Format to Give More Flexibility to Applicants)


Newsletter - September 28, 2017 (Is FDA Getting Impatient with Conventional Clinical Trials? | FDA Approvals Predominantly Based on Data Lacking Minority Subjects in Clinical Trials)

Newsletter - September 21, 2017 (Can FDA Regulate Stem Cell Companies if State Laws Allow Them | FDA Needs Consumers’ Help to Rein-in Online Pharmacies)

Newsletter - September 14, 2017 (Can FDA Do Anything About The Price of Drugs to Consumers | Expedited FDA Approval Leads to Unsafe Drugs? No.)

Newsletter - September 7, 2017 (The Practical Implications of FDA and EMA Sharing Confidential GMP Information | FDA Explains What is Real World Evidence and How It Can Be Used)

Newsletter - August 31, 2017 (No, FDA Did Not Change Stem Cell Regulations with One Announcement | Why Is Google’s Clinical Depression Tool Not a FDA-Regulated Medical Device)

Newsletter - August 24, 2017 (The Gray Area in FDA Regulation of Celebrity Endorsement of Drugs | FDA Updates Registration Requirements for Everybody Involved in Drug Distribution)


Newsletter - August 17, 2017 (Recruitment Issues with Cancer Trials Lead to Innovative Regulatory Scenarios | FDA’s Accelerated Approval Challenged, But Is it Fair to Blame the Agency?)

Newsletter - August 10, 2017 (The Promise and Perils of the Pre-Cert Program for Software Developers | FDA Explains What Is a Minor Change in Biologics Manufacturing: Core Principle for All GMP Process Changes)

Newsletter - August 3, 2017 (FDA Takes a Developer-Friendly Approach to Regulating Software | Automated System Improves FDA Clearance of Imports as Expected)

Newsletter - July 27, 2017 (FDA Looks Forward to Consumer Complaints to Rein In Supplements | Does Empowering Patients Mean “Better” Regulation of Drugs by FDA?)

Newsletter - July 20, 2017 (FDA Speeds Up Release of Drug Approval Information | Should Drugs Be Used After Expiration Dates to Manage Cost of Healthcare?)

Newsletter - July 13, 2017 (Why is India a Great Location for BA/BE Studies But Not For Clinical Trials? | Innovative Trial Design to Speed Up FDA Approval)


Newsletter - June 29, 2017 (FDA’s Pushes Generics in A Not-So-Indirect Effort to Control Drug Prices | Clinical Trial Endpoints Using Mobile Phones: Still a Lot of Ways to Go)

Newsletter - June 22, 2017 (FDA’s Guidance Lists Best Practices for Using Electronic Systems in Clinical Trials | Coconut Had a Bad Week but We All Got a Lesson in Food Health Claims)


Newsletter - June 15, 2017 (NIH Knee Jerk Reversal on Policy for Grants Limitation Raises New Questions | As Developers Push the Envelope with Smartphone Apps, FDA May Step Up too)

Newsletter - June 8, 2017 (Google Search Trends and Personal Health Management | Medical Devices for Rare Diseases No Longer Need to Use Local IRBs)

Newsletter - June 1, 2017 (Fidget Spinner: Should FDA Regulate or Leave Them Alone | FDA is Very Worried Device on Cybersecurity and So Should Be We)


Newsletter - May 25, 2017 (Two Unique Approvals in a Week; FDA’s Baby Steps, Industry’s Giant Leap | Janet Woodcock Pulled a Frances Kelsey and Everyone is Mad  )

​Newsletter - May 18, 2017 (Hacking of Computers in FDA Regulated Industries Exposes Common Flaw | NIH Limits on Grants to Investigators: First Step to Improve Distribution of Taxpayer Money)

​Newsletter - May 11, 2017 (Clinical Trials Cannot Catch All Side Effects of Drugs; Should We Worry | Privacy Concerns Limit Use of Genetic Data from DTC Tests)

​Newsletter - May 4, 2017 (Using Foreign Vendors? FDA’s Warning Letter Points A Common Issue | FDA and NIH Release the Best Free Tool to Write Clinical Protocols)

Newsletter - April 27, 2017 (FDA’s Action-Inaction About Unapproved Drugs | How Much Diversity is Required for FDA Approval?)


Newsletter - April 20, 2017 (Should Medical Food Clinical Trials be Conducted Under INDs? May be | What Are the Most Common GMP Deficiencies Found by FDA?)

Newsletter - April 13, 2017 (FDA’s Paradigm Shifting Approval of the First “Non-Diagnostic” Test | Who is Faster in Approving FDA or EMA and Why should it Matter)

Newsletter - April 6, 2017 (Off-Label Promotion Gets Political Support But Is It Good For Consumers | FDA Does Not Regulate Smartphone Apps, But Courts and FTC Do)


Newsletter - March 30, 2017 (FDA Audit Processes to Change Dramatically in May | Major Data Integrity Violations Exposes Flaws in the Regulatory Process)

Newsletter - March 23, 2017 (Special GMP for Cell Therapy Products: European Draft Guidance Gets Mixed Reviews | Time to Approval of 505(b)(2) NDAs is Shorter Than Conventional NDAs)

Newsletter - March 16, 2017 (Increased Patient Engagement by FDA and Its Impact on Industry | FDA Has Many Measures to Avoid Conflict of Interest)

Newsletter - March 9, 2017 (Over-Hyped Scientific Literature and FDA-Regulated Industry | Old Medicine, New Concerns: Should Hospitals Sell Alternative Medicine?)

Newsletter - March 2, 2017 (FDA Under Attack: Should Industry Help? | India is the Main Non-US Producer of Prescription Drugs)

Newsletter - February 23, 2017 (EMA Raises Concerns with Use of Electronic Systems in Clinical Trials | Small Companies Use Smart Strategies to be Successful with FDA)


Newsletter - February 16, 2017 (Compassionate Use Rules are Better Than the “Right to Try” Laws | Most Drug Approvals by FDA are Based on Clinical Trials in White People)

Newsletter - February 9, 2017 (Potential of Wearable Devices for Adverse Event Monitoring in Clinical Trials)

Newsletter - February 2, 2017 (No New FDA Regulations Means Keeping the Status Quo | Bringing Manufacturing to the US Will Not Reduce Drug Prices)

Newsletter - January 26, 2017 (Buying Public Opinion: Conflict of Interest and Discussions about Drugs | Data Integrity Issues in Clinical Trials due to Fraud by Patients)

Newsletter - January 19, 2017 (FDA Faces Many Challenges in Auditing Foreign GMP Sites | Convert or Inactivate DMFs Before the May Deadline for Electronic DMFs)

Newsletter - January 12, 2017 (Hacking Risks for Medical Devices with Internet Connectivity | Limitation of Real World Evidence Highlighted by Physician Survey)

Newsletter - January 5, 2017 (What Can We Expect From FDA This Year Based What We Saw Last Year)

    Newsletter Signup
    Subscribe to FDAMap Newsletter for 
    Refreshing Outlook on Regulatory Topics

Submit

Our Services

  • Workshops
  • Webinars
  • On-Demand Webinars
  • Custom training
  • Training Subscriptions
  • Corporate Registration
  • Certification Program
  • Smart Recruitment
  • Corporate Registration - Online Workshop​

Company

  • About Us​
  • Testimonials
  • Free Resources
  • Newsletter
  • Videos (Free Tutorials)

Support

  • Contact Us
  • Terms of Service
  • Privacy Policy
  • News Archive
Consultation Service
FDA Training Company
Copyright © 2022 FDAMap.com
Use of this Web site constitutes acceptance of the FDAMap Terms of Use and Privacy Policy.